Acute rash is a high-frequency, high-variability presentation in urgent care. Most eruptions are self-limited inflammatory, infectious, allergic, or exposure-related conditions; however, a small subset represents rapidly progressive infection, anaphylaxis, severe cutaneous adverse reaction, vasculitis, or a reportable communicable disease. The central task in an acute rash urgent care evaluation is not to name every morphology immediately. It is to identify time-sensitive danger, isolate when appropriate, establish a focused morphologic and exposure-based differential, and determine whether outpatient care is safe.

Clinical Overview

A rash is a cutaneous finding rather than a diagnosis. Diagnostic accuracy improves when the clinician describes lesions precisely before assigning a label: primary morphology (macule, papule, plaque, wheal, vesicle, pustule, bulla, nodule, petechia/purpura), configuration (grouped, annular, targetoid, linear), distribution, blanching status, mucosal involvement, tenderness, and temporal evolution.

In urgent care, an efficient approach is to answer four questions in sequence:

1. Is the patient unstable or at risk for rapid deterioration?
2. Does the rash require infection-control action or public-health notification?
3. What lesion pattern and exposure history most narrow the differential?
4. Can the patient be safely managed as an outpatient, and what reassessment threshold is appropriate?

Must-Not-Miss Diagnoses and Red Flags

Before a prolonged skin examination, obtain vital signs and assess appearance, airway, breathing, circulation, mentation, and pain severity. A rash with abnormal vital signs is not automatically dangerous, but fever, hypotension, tachycardia out of proportion, hypoxemia, altered mental status, toxic appearance, or rapidly evolving lesions should move the encounter toward emergency evaluation.

Immediate emergency transfer or EMS activation

• Anaphylaxis: acute skin or mucosal symptoms with respiratory compromise, hypotension/end-organ symptoms, or significant symptoms involving more than one organ system after a likely exposure. Urticaria alone is not anaphylaxis, but hypotension, wheeze, stridor, repetitive vomiting, syncope, or rapidly progressive facial/oral swelling is an emergency. Intramuscular epinephrine is first-line treatment and should not be delayed for antihistamines or corticosteroids.[1]
• Suspected meningococcemia or other invasive sepsis: fever or systemic illness with petechiae/purpura, severe extremity or abdominal pain, hypotension, neck stiffness, confusion, or rapidly progressive nonblanching lesions. Meningococcal disease can deteriorate within hours.[2]
• Severe cutaneous adverse reaction: painful dusky or targetoid lesions, blistering, epidermal detachment, extensive erosions, mucosal involvement, facial edema, fever, lymphadenopathy, or organ-system symptoms after a new medication. Consider Stevens-Johnson syndrome/toxic epidermal necrolysis, DRESS, and generalized bullous fixed drug eruption. Stop suspected culprit medications when clinically appropriate, but do not delay emergency transfer for diagnostic certainty.
• Necrotizing soft-tissue infection: severe pain out of proportion to examination, rapidly advancing erythema or edema, bullae, skin anesthesia, crepitus, ecchymosis, systemic toxicity, or failure to improve as expected. Do not attempt routine outpatient management when this is suspected.
• Ocular, neurologic, or disseminated herpes zoster: vesicles or pain in the ophthalmic trigeminal distribution, ocular symptoms, ear vesicles with facial weakness, altered mental status, extensive disseminated lesions, or immunocompromise requiring a higher level of care.
• High-risk febrile rash: suspected Rocky Mountain spotted fever (RMSF), measles, varicella in a high-risk host, or other serious systemic infection. Early negative testing does not safely exclude RMSF.[3]

Focused History

Use a short, reproducible history rather than an unfocused review of systems.

• Timing: exact onset; first lesion location; speed of spread; intermittent versus fixed lesions; relation to fever, travel, new medication, vaccination, infection, or exposure.
• Symptoms: pruritus, burning, pain, tenderness, fever, malaise, arthralgia, sore throat, cough/coryza/conjunctivitis, dyspnea, vomiting, diarrhea, headache, neck stiffness, dysuria, genital symptoms, and eye pain or visual change.
• Medication history: all prescription, over-the-counter, supplement, and intermittent medications started within the prior days to eight weeks. Ask specifically about antibiotics, anticonvulsants, allopurinol, nonsteroidal anti-inflammatory drugs, and prior reactions. Record timing of each exposure and whether the medication was continued after rash onset.
• Exposure history: ill contacts, household itch, daycare/school outbreaks, travel, hotel stays, occupational exposures, new cosmetics or detergents, plants, animals, arthropod bites, tick exposure, sexual exposure, and communal living settings.
• Host factors: age, pregnancy, immune suppression, HIV status when relevant, diabetes, chronic kidney or liver disease, malignancy, transplant, asplenia, eczema or chronic dermatoses, and vaccine history.

Pregnancy, infancy, frailty, immune compromise, and substantial renal or hepatic impairment lower the threshold for consultation, emergency evaluation, or medication adjustment.

Focused Examination

Examine the entire skin surface when feasible, including scalp, palms, soles, finger webs, nails, oral cavity, conjunctivae, genital/perianal area when indicated and consented to, and regional lymph nodes. Chaperone use and trauma-informed communication are important for sensitive examinations.

• Blanching: use a clear glass or firm fingertip pressure. Petechiae and purpura do not blanch; this finding must be interpreted with overall illness severity and evolution.
• Palpation: determine whether lesions are warm, indurated, fluctuant, tender, fixed, raised, or transient. Wheals usually migrate or resolve within 24 hours; painful lesions persisting in one location suggest an alternative diagnosis, including urticarial vasculitis or drug eruption.
• Mucosa and eyes: inspect for erosions, ulcers, conjunctivitis, injection, discharge, visual symptoms, or photophobia.
• Distribution clues: dermatomal grouped vesicles suggest zoster; honey-colored crusts suggest impetigo; burrows and nocturnal itch involving web spaces, wrists, waistline, axillae, or genitals suggest scabies; sharply patterned or linear lesions support contact dermatitis; acral rash involving palms and soles may occur with several viral, rickettsial, syphilitic, drug-related, and vasculitic processes.

Photograph lesions for the medical record only with institutional consent processes, appropriate privacy protections, and a note identifying site and date. Marking the leading edge of suspected cellulitis can assist reassessment, but it does not establish a diagnosis.

Pattern-Based Differential Diagnosis

Urticarial or angioedematous eruption

Typical urticaria consists of pruritic, blanching wheals that change location and resolve within 24 hours at an individual site. Ask about food, medication, venom, infection, exertion, heat/cold, and new exposures. Screen actively for anaphylaxis. Isolated uncomplicated urticaria may be managed as an outpatient when vital signs are normal and there are no respiratory, cardiovascular, gastrointestinal, or progressive mucosal symptoms.

Morbilliform/maculo-papular eruption

Common considerations include viral exanthem, uncomplicated drug eruption, and contact-related dermatitis. In adults, a new diffuse morbilliform eruption after a recently initiated medication deserves careful review for fever, facial edema, mucosal lesions, skin pain, lymphadenopathy, eosinophilia, hepatitis, nephritis, or blistering. Those findings are not compatible with a reassuring “simple drug rash” assessment.

Vesicular, bullous, or pustular eruption

Grouped vesicles on an erythematous base in a unilateral dermatome support herpes zoster. Herpes simplex, allergic contact dermatitis, impetigo, arthropod reactions, varicella, and mpox may resemble it. Zoster is generally clinical, but lesion PCR can help when the appearance is atypical, in immunocompromised patients, or when the result will alter infection-control or treatment decisions. PCR from vesicle fluid, scabs, or cells collected from the lesion base is preferred for varicella-zoster virus confirmation.[4]

Diffuse vesicles in multiple stages with fever may represent varicella. Isolate promptly and assess for pregnancy, immune compromise, neonatal exposure, and respiratory symptoms. Patients with varicella are contagious from approximately one to two days before rash onset until lesions crust; vaccinated patients with noncrusting lesions remain contagious until no new lesions have appeared for 24 hours.[5]

Crusted, erosive, or localized bacterial-appearing rash

Nonbullous impetigo typically produces superficial erosions and honey-colored crust. Ecthyma is deeper and ulcerative. Culture purulent material or exudate when disease is recurrent, extensive, atypical, treatment-resistant, associated with outbreaks, or when local resistance data will change therapy; empiric treatment without culture is reasonable in a classic limited presentation.[6] Diffuse erythema diagnosed as “cellulitis” should be warm, tender, expanding, and clinically coherent; bilateral chronic erythema with scale and itch more often reflects a noninfectious mimic.

Scabies and infestation

Think of scabies when intense nocturnal pruritus occurs in the patient and contacts, particularly with papules, nodules, excoriations, or burrows on hands, wrists, axillae, beltline, buttocks, breasts, or genital skin. Infants, young children, and older adults may have scalp, face, or neck involvement. Crusted scabies is highly transmissible and occurs more often in older, debilitated, neurologically impaired, or immunocompromised patients; it requires aggressive combined treatment and often public-health or facility coordination.[7]

Febrile petechial/purpuric rash

This category requires a high-acuity mindset. Consider invasive bacterial infection, RMSF and other rickettsioses, vasculitis, thrombocytopenia/coagulopathy, endocarditis, and severe viral illness. Ask about tick exposure and outdoor activity, but absence of a recalled bite does not exclude RMSF. Do not wait for a classic rash pattern or confirmatory testing when the clinical syndrome is compatible; treatment delay increases risk.[3]

Diagnostic Approach and Point-of-Care Testing

Most uncomplicated rashes are clinical diagnoses. Testing should answer a focused question rather than substitute for examination.

• Pregnancy test: obtain when pregnancy is possible and medication choice, imaging, referral urgency, or varicella exposure management could change.
• Rapid streptococcal testing: consider for a compatible scarlatiniform rash with pharyngitis; test performance and follow-up throat-culture practices vary by age and local policy.
• VZV/HSV PCR: useful for atypical vesicular disease, immunocompromised patients, or uncertain infection-control decisions. Collect from a fresh vesicle, scab, or vigorously sampled lesion base according to laboratory instructions.[4]
• Bacterial wound culture: useful for purulent drainage, recurrent abscesses, ecthyma, treatment failure, unusual exposure, or substantial antibiotic-resistance concern. Do not culture intact nonpurulent skin routinely.
• CBC, metabolic panel, liver tests, urinalysis: consider when systemic illness, possible DRESS, vasculitis, dehydration, suspected rickettsial infection, or organ involvement is present. Normal early results do not rule out dangerous disease.

If measles is plausible, mask the patient before rooming, place them in airborne isolation if available, minimize staff exposure, notify public health promptly, and arrange recommended serum plus respiratory testing. Measles classically presents with fever, cough, coryza, conjunctivitis, Koplik spots, and then a maculopapular rash, but presentation may be modified in partially immune patients.[8]

Management in Urgent Care

Anaphylaxis

For suspected anaphylaxis, administer epinephrine 1 mg/mL intramuscularly into the mid-outer thigh promptly. Typical dosing is 0.01 mg/kg per dose, with a usual maximum of 0.5 mg in adults and 0.3 mg in prepubertal children; repeat doses may be needed every 5 to 15 minutes based on response. Activate EMS, position the patient appropriately, provide oxygen and monitoring as indicated, establish intravenous access when feasible, and transfer for emergency evaluation. Antihistamines may improve itching or hives but do not treat airway edema, shock, or bronchospasm and must not delay epinephrine.[1] Document suspected trigger, timing, dose, route, response, and transfer handoff.

Uncomplicated inflammatory dermatitis

For a localized, noninfected dermatitis pattern, avoidance of the suspected trigger, bland emollients, cool compresses, and an appropriately selected topical corticosteroid are common outpatient measures. Potency, vehicle, frequency, and duration must be matched to age, body site, disease severity, and skin integrity. Use lower-potency therapy and shorter courses on the face, eyelids, intertriginous skin, genitals, and in young children; avoid routine use of potent agents on thin skin. Topical corticosteroids and moisturizers are established components of atopic dermatitis care, but clinicians should reconsider the diagnosis if lesions are painful, vesicular, purulent, widespread, or accompanied by fever.[9]

Impetigo and uncomplicated superficial bacterial infection

For limited impetigo, mupirocin 2% topical applied to affected lesions twice daily for 5 days is an IDSA-supported option. For numerous lesions, ecthyma, or circumstances where topical therapy is impractical, an oral regimen may be needed. Typical adult examples include cephalexin 500 mg orally four times daily for 7 days when methicillin-susceptible staphylococci and streptococci are expected, or an agent active against community MRSA when clinically indicated by local epidemiology or culture results.[6] Antibiotic selection must account for allergy phenotype, pregnancy, renal function, hepatic disease, drug interactions, local resistance patterns, and whether streptococcal coverage is needed. Doxycycline and trimethoprim-sulfamethoxazole have limitations in pregnancy and may not reliably cover streptococci; cephalexin requires renal-dose adjustment. Verify current local guidance and dosing before prescribing.

Herpes zoster

For uncomplicated zoster in an appropriate outpatient, antiviral therapy is most effective when started within 72 hours of symptom onset and may still be considered later when new lesions are forming or complications are present.[10] A typical adult regimen is valacyclovir 1 g orally three times daily for 7 days. Reduce the dose in renal impairment; higher-than-recommended exposure can contribute to neurotoxicity and renal adverse effects, particularly in older adults or those with kidney disease.[11] Valacyclovir is contraindicated in patients with clinically significant hypersensitivity to valacyclovir or acyclovir. Pregnancy, immunocompromise, severe hepatic or renal disease, disseminated disease, and eye/ear involvement warrant a lower threshold for specialist or emergency evaluation. Counsel patients to cover lesions, avoid touching lesions, wash hands, and avoid contact with nonimmune pregnant people, premature infants, and immunocompromised individuals until lesions have crusted.[10]

Scabies

For classic scabies, permethrin 5% cream is applied to the entire body from the neck down and washed off after 8 to 14 hours; a second application about one week later is commonly used when needed. It is FDA-approved for patients at least 2 months old.[7] In young children, older adults, and others with scalp involvement, follow product and specialty guidance regarding head/neck application. Oral ivermectin is an alternative in selected patients: 200 micrograms/kg orally with food, repeated in 7 to 14 days. It is not FDA-approved for scabies in the United States, and safety has not been established in pregnancy or in children weighing less than 15 kg.[7] Treat close contacts concurrently when appropriate, launder or heat-dry bedding/clothing used recently, and explain that pruritus may persist after successful eradication. Crusted scabies should not be managed with a casual single-agent regimen; combined therapy and outbreak-control planning are required.[7]

Suspected RMSF or other serious tick-borne rickettsial disease

When the syndrome is clinically compatible, initiate treatment and arrange emergency-level assessment rather than waiting for confirmatory testing. Typical dosing is doxycycline 100 mg orally or intravenously every 12 hours for adults; children weighing less than 45 kg receive 2.2 mg/kg per dose every 12 hours. Treat for at least 3 days after fever resolves and clinical improvement occurs, with a minimum 5- to 7-day course.[3] CDC recommends doxycycline for suspected RMSF in patients of all ages, including pregnant patients, because delayed or alternative therapy is associated with worse outcomes; pregnancy counseling should address the benefit-risk context and involve obstetric expertise when feasible.[3] Severe doxycycline allergy requires emergency/specialist management rather than substitution with an ineffective routine outpatient antibiotic.

Disposition, Follow-Up, and Counseling

Outpatient treatment is reasonable only when the patient is hemodynamically stable, has no high-risk morphology or mucosal/ocular involvement, has reliable follow-up, and can understand return precautions. Arrange reassessment within 24 to 48 hours for uncertain diagnoses, evolving bacterial infection, high-risk hosts, or treatment started empirically.

Emergency precautions should be explicit: new or worsening shortness of breath; lip, tongue, or throat swelling; fainting; high fever or toxic appearance; confusion; severe headache or neck stiffness; rapidly spreading rash; nonblanching purple lesions; severe skin pain; blistering or peeling; eye pain or visual symptoms; inability to hydrate; or worsening despite treatment.

Documentation Considerations

• Describe morphology, distribution, extent, blanching status, tenderness, mucosal/ocular findings, and whether lesions are fixed or transient.
• Record vital signs, systemic symptoms, medication/exposure timeline, pregnancy status when relevant, immune status, and infection-control actions.
• Document diagnostic uncertainty and the rationale for outpatient care, transfer, testing, empiric therapy, or consultation.
• For suspected drug eruption, list all potential culprit medications with start dates and document whether discontinuation was advised or deferred because of therapeutic necessity.
• For transfer, document emergency treatments, response, receiving facility, transport mode, and handoff details.

Clinical Takeaways

• Describe the eruption before labeling it; morphology plus time course is more useful than color alone.
• Rash with instability, mucosal involvement, skin pain, nonblanching lesions, blistering, ocular symptoms, or systemic toxicity requires escalation.
• Consider infection-control requirements early for measles, varicella, disseminated zoster, and other contagious exanthems.
• Do not delay epinephrine for suspected anaphylaxis or doxycycline for clinically compatible RMSF.
• Medication regimens in this article are representative, not universal. Independently verify current dosing, labeling, contraindications, pregnancy/lactation information, renal/hepatic adjustments, interactions, local resistance patterns, and institutional protocols before clinical use.

References

1. Golden DBK, Wang J, Waserman S, Akin C, Campbell RL, Ellis AK, et al. Anaphylaxis: a 2023 practice parameter update. Ann Allergy Asthma Immunol. 2024;132(2):124-176. doi:10.1016/j.anai.2023.09.015.
2. Centers for Disease Control and Prevention. Meningococcal disease symptoms and complications [Internet]. Atlanta (GA): CDC; 2026 [cited 2026 Aug 16].
3. Centers for Disease Control and Prevention. Clinical care of Rocky Mountain spotted fever [Internet]. Atlanta (GA): CDC; 2025 [cited 2026 Aug 16].
4. Centers for Disease Control and Prevention. Laboratory testing for varicella-zoster virus (VZV) [Internet]. Atlanta (GA): CDC; 2024 [cited 2026 Aug 16].
5. Centers for Disease Control and Prevention. Clinical overview of chickenpox (varicella) [Internet]. Atlanta (GA): CDC; 2024 [cited 2026 Aug 16].
6. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJC, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-e52. doi:10.1093/cid/ciu296.
7. Centers for Disease Control and Prevention. Clinical care of scabies [Internet]. Atlanta (GA): CDC; 2023 [cited 2026 Aug 16].
8. Centers for Disease Control and Prevention. Clinical overview of measles [Internet]. Atlanta (GA): CDC; 2026 [cited 2026 Aug 16].
9. American Academy of Dermatology. Atopic dermatitis clinical guideline [Internet]. Rosemont (IL): American Academy of Dermatology; 2026 [cited 2026 Aug 16].
10. Centers for Disease Control and Prevention. Clinical overview of shingles (herpes zoster) [Internet]. Atlanta (GA): CDC; 2024 [cited 2026 Aug 16].
11. GlaxoSmithKline LLC. Valtrex (valacyclovir hydrochloride) tablets: prescribing information [Internet]. Bethesda (MD): National Library of Medicine, DailyMed; 2025 [cited 2026 Aug 16].

Educational disclaimer: This clinician-facing article is intended for professional education and does not replace clinical judgment, local protocols, specialist consultation, emergency transfer when indicated, or current prescribing information and guidelines. It is not individualized medical advice for any patient.

Cellulitis is an acute bacterial infection of the dermis and subcutaneous tissue that usually presents with expanding erythema, warmth, tenderness, and edema. Although commonly managed in ambulatory settings, it is a high-error diagnosis: venous stasis dermatitis, inflammatory edema, contact dermatitis, gout, deep vein thrombosis (DVT), abscess, and other conditions may closely resemble infection. A rigorous approach to cellulitis urgent care evaluation therefore depends as much on identifying mimics and occult complications as on selecting an antibiotic.[1,4]

Clinical overview

Most uncomplicated, nonpurulent cellulitis is caused by beta-hemolytic streptococci; Staphylococcus aureus, usually methicillin-susceptible, may contribute in selected cases. Cellulitis is a diffuse infection without a drainable collection. A pustule, spontaneous purulent drainage, fluctuant mass, or focal point of maximal tenderness should prompt reconsideration of the diagnosis and assessment for abscess, septic bursitis, infected cyst, or another suppurative process. Drainage—not antibiotics alone—is central to abscess management.[1,2]

Clinical severity is determined by systemic illness, speed of progression, pain severity, anatomic site, host factors, ability to take oral medication, likelihood of follow-up, and concern for deeper infection. Urgent care is appropriate for selected stable patients with mild nonpurulent disease; emergency department (ED) transfer is appropriate when sepsis, necrotizing infection, orbital involvement, rapidly progressive disease, or a need for advanced imaging, parenteral therapy, surgical consultation, or inpatient monitoring is suspected.[1]

Etiology and risk factors

Cellulitis often follows an imperceptible breach in the skin barrier. Ask specifically about trauma, shaving, insect bites, punctures, ulcers, fissured toe webs, eczema, tinea pedis, recent surgery, injection drug use, and bites. Lower-extremity disease is associated with chronic edema, lymphedema, venous insufficiency, obesity, and prior episodes. Diabetes, peripheral arterial disease, neuropathy, immunosuppression, and chronic wounds increase both diagnostic complexity and the risk of poor outcomes.[1,2]

Exposure history changes the likely microbiology and disposition. Water exposure, animal or human bites, penetrating trauma through footwear, burns, postoperative wounds, neutropenia, and severe immunocompromise may require culture, broader therapy, specialist input, or ED evaluation rather than routine uncomplicated-cellulitis treatment.[1,2]

Typical clinical presentation

Typical cellulitis is unilateral and develops over hours to several days. Findings include ill-defined erythema, warmth, tenderness, swelling, and sometimes regional lymphangitis or lymphadenopathy. Fever, chills, malaise, tachycardia, and leukocytosis may occur but are not required. Erysipelas is often more superficial, bright red, and sharply demarcated; management principles overlap.

On darker skin tones, erythema may be subtle or difficult to assess. Compare with the contralateral side and document warmth, edema, tenderness, induration, skin texture, drainage, and functional change rather than relying on redness alone. When practical, outline the involved area with a skin marker and document date and time; serial photographs with appropriate consent and institutional privacy safeguards can support reassessment.[3]

Focused history

• Time of onset, rate of spread, preceding lesion, trauma, wound, surgery, bite, injection, or water exposure.
• Local symptoms: pain severity, pruritus, drainage, fluctuance, blistering, numbness, weakness, reduced range of motion, or pain with passive movement.
• Systemic symptoms: fever, rigors, vomiting, confusion, dizziness, syncope, or poor oral intake.
• Prior cellulitis, abscesses, MRSA infection or colonization, recent hospitalization, recent antibiotics, or household MRSA exposure.
• Diabetes, vascular disease, lymphedema, venous disease, neuropathy, chronic kidney or liver disease, malignancy, neutropenia, transplant status, biologic therapy, and systemic corticosteroid use.
• Medication list, renal function when known, anticoagulants, pregnancy or lactation status, and a detailed allergy history. Distinguish intolerance from immediate hypersensitivity, anaphylaxis, angioedema, severe cutaneous adverse reaction, or a remote nonurticarial rash.
• For a swollen leg, assess DVT risk factors: prior venous thromboembolism, active cancer, recent surgery or immobilization, pregnancy/postpartum status, estrogen exposure, and unilateral calf symptoms.

Focused examination

Record full vital signs and general appearance before focusing on the skin. Examine and palpate the entire affected region, adjacent joints, regional lymph nodes, and the contralateral limb. Measure or estimate dimensions. Look for portal of entry, interdigital maceration, ulcers, foreign body, eschar, bullae, crepitus, necrosis, drainage, fluctuance, lymphangitis, and disproportionate tenderness.

Perform and document neurovascular assessment when an extremity is involved: distal pulses when clinically relevant, capillary refill, sensation, motor function, and compartment firmness. Evaluate joint range of motion and pain with active and passive movement when infection overlies or is near a joint. Examine feet carefully in lower-extremity presentations, including between toes, for tinea, fissures, and maceration.[1,2]

Differential diagnosis

• Abscess, furuncle, infected epidermoid cyst, or septic bursitis: focal fluctuance, purulence, a palpable cavity, or focal tenderness may be present. These are not simple nonpurulent cellulitis.
• Venous stasis dermatitis, lipodermatosclerosis, and lymphedema: often chronic, bilateral or recurrent, pruritic, scaling, hyperpigmented, or associated with longstanding edema.
• Contact dermatitis or arthropod reaction: pruritus, vesiculation, sharply patterned exposure, or a central punctum may favor a noninfectious process.
• DVT or superficial thrombophlebitis: unilateral swelling and tenderness may overlap; obtain definitive venous imaging when pretest probability warrants it.
• Crystal arthritis, septic arthritis, or inflammatory arthritis: joint-centered pain, effusion, and painful restricted passive range of motion require careful assessment.
• Herpes zoster: dermatomal pain with grouped vesicles.
• Osteomyelitis, diabetic foot infection, ischemia, and pressure injury: consider in chronic ulcers, neuropathy, exposed bone, deep wounds, or vascular compromise.

There is no single confirmatory test for cellulitis, and diagnostic error is frequent. A systematic review found that many alternative diagnoses were noninfectious, particularly stasis dermatitis, eczematous dermatitis, and edema/lymphedema. Reassessment is therefore a clinical safety intervention, not merely a treatment-failure check.[4]

Must-not-miss diagnoses and emergency red flags

Transfer to an ED by emergency medical services when clinically indicated; do not delay transfer for outpatient testing or oral treatment if any of the following are present:

• Hypotension, altered mental status, toxic appearance, persistent tachycardia, tachypnea, hypoxia, rigors, or other sepsis physiology.
• Pain out of proportion to examination, rapidly advancing erythema or edema, skin anesthesia, dusky discoloration, hemorrhagic bullae, crepitus, necrosis, or gas on imaging: concern for necrotizing soft-tissue infection.
• Periorbital or orbital symptoms, including pain with eye movement, ophthalmoplegia, proptosis, vision change, severe headache, or toxic appearance.
• Suspected septic arthritis, flexor tenosynovitis, deep hand-space infection, compartment syndrome, osteomyelitis, ischemic limb, or an infected diabetic foot with deep tissue involvement.
• Rapid progression despite appropriate initial therapy; inability to tolerate oral medication; uncontrolled pain; major functional impairment; or unreliable access to timely reassessment.
• Severe immunocompromise, severe neutropenia, major trauma, bite injury with significant infection, immersion injury, or concern for unusual organisms.

Necrotizing infection is primarily a clinical diagnosis. Normal early laboratory values, lack of fever, or absence of crepitus does not reliably exclude it. Obtain urgent surgical evaluation and emergency transfer when suspected.[1]

Diagnostic approach and point-of-care testing

Uncomplicated cellulitis is generally a clinical diagnosis. Routine wound cultures, skin aspirates, biopsies, and blood cultures are not recommended for typical nonpurulent cases because yield is low and results seldom change outpatient care. Culture purulent drainage whenever feasible and consider blood cultures or targeted microbiologic testing in severe systemic illness, immunocompromise, animal bites, immersion injuries, or other atypical exposures.[1,2]

Point-of-care ultrasound (POCUS) is useful when physical examination cannot confidently distinguish cellulitis from abscess. Cobblestoning supports interstitial edema but is not specific for infection; a discrete fluid collection, posterior enhancement, or internal debris supports abscess. POCUS should be performed only by clinicians trained and credentialed under local policy. A negative scan does not exclude deep infection, early abscess, DVT, septic arthritis, or necrotizing infection.[5]

Obtain targeted tests when they will change disposition or treatment. Examples include point-of-care glucose in patients with diabetes or systemic illness; pregnancy testing when it affects medication or imaging decisions; complete blood count, metabolic panel, lactate, blood cultures, radiography, formal vascular ultrasound, CT, or MRI in patients being transferred or evaluated for complication. Do not use a normal white blood cell count or normal inflammatory marker as reassurance when the examination suggests a deep or severe infection.

Outpatient management

Supportive measures

• Elevate the involved extremity when feasible and encourage movement within pain and safety limits.
• Address the portal of entry: cleanse superficial wounds, provide appropriate wound care, and treat toe-web fissuring, maceration, or tinea pedis when present.
• Use analgesia appropriate to the patient’s comorbidities and medication profile. Acetaminophen is often an option; nonsteroidal anti-inflammatory drugs require individualized assessment for renal disease, gastrointestinal risk, anticoagulation, heart failure, and pregnancy.
• Mark the border and arrange a defined reassessment plan. Early extension across the border can occur despite appropriate therapy, but rapid progression or systemic deterioration is not expected and requires reassessment.

Antibiotic selection

For mild, uncomplicated nonpurulent cellulitis, choose an oral agent active against streptococci. In the United States, cephalexin is a common outpatient option when there is no serious beta-lactam allergy. IDSA recommends a 5-day course for most patients, extending only when clinical improvement is inadequate. Local antibiograms, prior cultures, allergy phenotype, renal function, exposure history, and formulary availability should guide selection.[1,2]

• Cephalexin: common adult regimen for uncomplicated nonpurulent cellulitis is 500 mg orally every 6 hours for 5 days; some clinicians use 500 mg orally every 8 hours depending on local protocol and patient factors. It covers streptococci and methicillin-susceptible S. aureus, not MRSA. Renally adjust; labeling limits the daily dose to 1 g when creatinine clearance is 30–59 mL/min and provides lower-dose schedules for more severe renal impairment. Avoid in known cephalosporin hypersensitivity and carefully evaluate a history of immediate severe beta-lactam reaction. Counsel regarding rash, anaphylaxis symptoms, and antibiotic-associated diarrhea; review metformin and probenecid use. The product label lists pediatric dosing for children older than 1 year as 25–50 mg/kg/day orally in divided doses, with 50–100 mg/kg/day for severe infections; use a current pediatric reference for indication-specific interval and maximum dose rather than extrapolating from adult treatment.[6]
• Clindamycin: may be considered when an oral agent with both streptococcal and community-associated MRSA activity is needed and susceptibility supports use, or when beta-lactams cannot be used. A typical adult regimen is 300–450 mg orally every 6–8 hours for about 5 days, individualized to severity and local guidance. It carries a meaningful risk of Clostridioides difficile infection; counsel patients to seek care for significant or persistent diarrhea. Consider hepatic impairment, prior C. difficile, and local clindamycin resistance, including inducible resistance when cultures are available.
• Doxycycline: a typical adult MRSA-active regimen is 100 mg orally twice daily for about 5 days. Doxycycline has unreliable streptococcal activity; when used for a nonpurulent presentation in which both MRSA and streptococcal coverage are desired, pair it with an appropriate beta-lactam if the patient can take one, rather than using doxycycline alone. Avoid routine use during pregnancy and generally avoid in children younger than 8 years unless a specific indication outweighs risk. Counsel regarding photosensitivity, esophagitis prevention with water and upright administration, and separation from polyvalent cations.
• Trimethoprim-sulfamethoxazole (TMP-SMX): a common adult MRSA-active regimen is 1–2 double-strength tablets (160 mg/800 mg each) orally twice daily for about 5 days, with the exact regimen individualized. It also has unreliable streptococcal coverage, so pair with a streptococcal-active agent when both are required. Renal dose adjustment and monitoring considerations are important. Review sulfonamide allergy, pregnancy timing, folate status, kidney disease, hyperkalemia risk, and interacting medicines such as ACE inhibitors, angiotensin receptor blockers, spironolactone, and warfarin.
• Amoxicillin-clavulanate: is not a routine first-line choice for ordinary nonpurulent cellulitis but is often appropriate for infected animal or human bites because aerobic and anaerobic coverage is needed. A common adult regimen is 875 mg/125 mg orally every 12 hours, with duration and renal adjustment determined by wound severity and local guidance. Do not use as a substitute for MRSA coverage when MRSA is the primary concern.[1]

Routine addition of TMP-SMX to cephalexin for uncomplicated cellulitis without abscess or purulent drainage did not improve clinical resolution in a large randomized trial. MRSA-active therapy should therefore be deliberate rather than reflexive. IDSA identifies penetrating trauma, MRSA infection elsewhere or colonization, injection drug use, and systemic inflammatory response as settings that increase concern for MRSA; illness of this severity often warrants ED-level assessment rather than routine urgent-care oral therapy.[1,7]

Pregnancy, pediatrics, older adults, and organ impairment: In pregnancy, confirm the diagnosis and coordinate with obstetric care when disease is moderate, rapidly progressive, facial, recurrent, or associated with systemic symptoms. Beta-lactams are often preferred when appropriate; avoid assuming that doxycycline or TMP-SMX is suitable without gestational-age-specific review. Pediatric cellulitis requires weight-based dosing, maximum-dose verification, and lower thresholds for ED referral in infants, toxic-appearing children, facial/periorbital disease, rapid progression, immunocompromise, or concern for nonaccidental trauma. In older adults, assess renal function, delirium risk, adherence, fall risk, vascular disease, polypharmacy, and the possibility of noninfectious edema or dermatitis. Independently verify renal and hepatic dosing, drug interactions, contraindications, and local resistance patterns before prescribing any regimen.

Procedures

Do not perform incision and drainage for cellulitis without a drainable collection. If POCUS or examination identifies an abscess, manage it as an abscess under a separate procedure protocol with consent, analgesia/anesthesia, sterile preparation, drainage, culture when indicated, wound care, and documented reassessment. Do not attempt routine urgent-care drainage of suspected deep hand-space infection, infection near critical neurovascular structures, perirectal or genital infection, suspected necrotizing infection, deep or complex abscess, or abscess in a patient requiring procedural sedation or surgical consultation.

Disposition, follow-up, and expected course

Outpatient care is reasonable when the patient is hemodynamically stable, does not have altered mental status or systemic inflammatory response, can take and absorb oral medication, has no concern for deeper infection, and can obtain prompt follow-up.[1] Arrange reassessment in 24–48 hours for patients with diagnostic uncertainty, substantial edema, borderline severity, high-risk comorbidity, or any concern about progression; otherwise, instruct patients to seek reassessment if symptoms do not begin improving within 48–72 hours. The involved skin may remain discolored, swollen, or tender after antibiotics are completed; improvement in pain, warmth, spread, and systemic symptoms is more informative than immediate disappearance of erythema.[3]

At reassessment, confirm adherence, evaluate vital signs, compare with marked borders or photographs, and reconsider the diagnosis. Apparent treatment failure may reflect abscess, incorrect diagnosis, inadequate source control, nonadherence, resistant or unusual pathogen, persistent edema, arterial disease, or a deep infection requiring imaging or specialty evaluation.

Return and emergency precautions

Provide explicit written precautions. Patients should seek urgent reassessment immediately for fever or rigors, fainting, confusion, rapidly spreading redness, worsening swelling, severe or disproportionate pain, new bullae, purple/black discoloration, numbness, weakness, vomiting or inability to take medication, new drainage, or no meaningful improvement within the specified follow-up interval. Instruct patients with facial or periorbital symptoms, vision change, pain with eye movement, hand dysfunction, or a cold/pale extremity to seek emergency care immediately.

Documentation considerations

• Onset, progression, portal of entry, exposure history, prior episodes, antibiotic/MRSA history, and relevant comorbidities.
• Vital signs, systemic appearance, lesion location and measurements, skin descriptors, presence or absence of purulence/fluctuance/crepitus/bullae/necrosis, neurovascular status, joint findings, and toe-web examination when relevant.
• Differential diagnosis and why DVT, abscess, necrotizing infection, septic joint, dermatitis, or other key alternatives are less or more likely.
• Testing performed, POCUS findings when used, culture source if obtained, and rationale for not obtaining routine cultures or labs when appropriate.
• Antibiotic rationale, allergy assessment, renal/hepatic considerations, interaction review, pregnancy considerations when relevant, supportive treatment, border marking, follow-up interval, and specific ED precautions.

Clinical takeaways

• Cellulitis is a clinical diagnosis; actively look for mimics and occult abscess rather than treating every red swollen extremity as infection.
• Nonpurulent cellulitis generally requires streptococcal coverage, not automatic MRSA coverage.
• Purulence or a fluid collection changes the problem: source control becomes central.
• Sepsis, pain out of proportion, rapidly progressive change, bullae, necrosis, orbital findings, deep-structure concern, or severe host vulnerability requires emergency escalation.
• A carefully documented 24–72 hour reassessment plan is essential to safe urgent-care management.

References

1. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJC, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-e52. doi:10.1093/cid/ciu296.
2. Centers for Disease Control and Prevention. Clinical guidance for group A streptococcal cellulitis [Internet]. Atlanta (GA): CDC; 2025 Aug 5 [cited 2026 Aug 16].
3. National Institute for Health and Care Excellence. Cellulitis and erysipelas: antimicrobial prescribing. NICE guideline NG141 [Internet]. London: NICE; 2019 Sep 27 [cited 2026 Aug 16].
4. Nightingale R, Yadav K, Hamill L, Glasziou P, Scott AM, Clark J, et al. Misdiagnosis of uncomplicated cellulitis: a systematic review and meta-analysis. J Gen Intern Med. 2023;38(10):2396-2404. doi:10.1007/s11606-023-08229-w.
5. American College of Emergency Physicians. Ultrasound guidelines: emergency, point-of-care, and clinical ultrasound guidelines in medicine. Ann Emerg Med. 2023;81(3):e1-e29.
6. Cephalexin capsule [prescribing information]. DailyMed [Internet]. Bethesda (MD): National Library of Medicine; revised 2026 Jul [cited 2026 Aug 16].
7. Moran GJ, Krishnadasan A, Mower WR, Abrahamian FM, LoVecchio F, Steele MT, et al. Effect of cephalexin plus trimethoprim-sulfamethoxazole vs cephalexin alone on clinical cure of uncomplicated cellulitis: a randomized clinical trial. JAMA. 2017;317(20):2088-2096. doi:10.1001/jama.2017.5653.

Educational disclaimer: This article is intended for clinician education and does not replace patient-specific clinical judgment, local protocols, specialist consultation, drug labeling, or current guidelines. Medication doses, contraindications, interactions, renal/hepatic adjustments, pediatric maximum doses, pregnancy considerations, and local resistance data must be independently verified before clinical use.

Abscess incision and drainage (I&D) is a common urgent care procedure and is the primary treatment for most uncomplicated cutaneous abscesses. Successful outpatient care depends less on prescribing antibiotics than on correctly identifying a drainable collection, achieving adequate evacuation and disruption of loculations, recognizing high-risk anatomy or deep infection, and arranging appropriate reassessment. This guide addresses routine superficial skin abscess management; clinicians should independently verify current institutional protocols, medication dosing, product labeling, local antibiograms, and referral pathways before clinical use.

Clinical overview

A cutaneous abscess is a localized collection of pus in the dermis or subcutaneous tissue. It commonly presents as a painful, tender, erythematous, fluctuant nodule, sometimes with a central pustule or spontaneous drainage. Staphylococcus aureus, including community-associated methicillin-resistant S. aureus (MRSA), is a frequent cause. Purulent lesions described by patients as “spider bites” should prompt consideration of staphylococcal infection, including MRSA. [1,2]

For a drainable abscess, I&D is the essential intervention. Antibiotics may improve outcomes for selected patients after drainage, but they do not replace drainage when a meaningful purulent collection is present. [1,3,4]

Clinical significance, etiology, and risk factors

Abscess formation follows inoculation of bacteria through disrupted skin, hair follicles, minor trauma, shaving, friction, injection drug use, or preexisting dermatoses. Pus accumulates in a cavity that is relatively poorly penetrated by systemic antibiotics; source control is therefore critical. Furuncles arise from infected hair follicles, while carbuncles are deeper coalescent infections of contiguous follicles. Inflamed epidermoid cysts may mimic abscesses but can contain keratinous material and may be predominantly inflammatory rather than infectious. [1]

Important risk factors include prior MRSA infection or colonization, close-contact living environments, contact sports, diabetes, obesity, tobacco use, hidradenitis suppurativa, chronic skin disease, immunosuppression, injection drug use, recent surgery, and retained foreign material. Recurrent lesions in the axillae, groin, inframammary folds, or buttocks should raise concern for hidradenitis suppurativa. A recurrent abscess at one specific site warrants assessment for a cyst, sinus tract, pilonidal disease, foreign body, or other local anatomic cause. [1]

Focused history

• Onset, progression, spontaneous drainage, prior episodes, and preceding trauma, shaving, bite, injection, procedure, or surgery.
• Fever, rigors, malaise, rapidly progressive pain, vomiting, confusion, or other systemic symptoms.
• Location-specific symptoms: pain with eye movement or vision change; dental pain; dysphagia; rectal pain; urinary symptoms; breast symptoms; joint pain or restricted motion; genital pain or swelling.
• Diabetes, renal or hepatic disease, immune compromise, chemotherapy, chronic corticosteroid use, neutropenia, HIV, anticoagulant or antiplatelet therapy, and prosthetic material.
• Pregnancy or possibility of pregnancy; breastfeeding status.
• Medication allergies, prior antimicrobial adverse events, current medications that increase risk of hyperkalemia or bleeding, and prior culture results.
• MRSA history in the patient or household, recurrent infections, and barriers to 24- to 48-hour follow-up.

Focused examination

Record complete vital signs before the procedure. Examine the lesion for size, fluctuance, induration, pointing, central necrosis, active drainage, surrounding erythema, lymphangitis, bullae, crepitus, skin anesthesia, and pain out of proportion to examination. Measure and document the area of erythema and the suspected abscess dimensions. Assess distal neurovascular status and active range of motion when lesions involve an extremity or lie near a joint, tendon, or neurovascular bundle.

Examine regional lymph nodes when clinically relevant. Do not anchor on “abscess” when the lesion is unusually painful, fixed, pulsatile, ulcerated, recurrent at an atypical site, associated with a deep mass, or accompanied by disproportionate systemic illness.

Differential diagnosis

• Cellulitis without drainable collection.
• Furuncle, carbuncle, infected epidermoid cyst, hidradenitis suppurativa, or pilonidal disease.
• Hematoma, seroma, inflamed lymph node, thrombosed superficial vein, bursitis, or foreign-body reaction.
• Herpes simplex, zoster, arthropod reaction, pyoderma gangrenosum, vasculitis, or malignancy.
• Septic bursitis, septic arthritis, flexor tenosynovitis, deep-space hand infection, odontogenic infection, perirectal abscess, or breast abscess.
• Necrotizing soft-tissue infection or myonecrosis.

Must-not-miss diagnoses and emergency transfer criteria

Do not attempt routine urgent care I&D when emergency department evaluation, surgical consultation, specialty management, advanced imaging, intravenous therapy, or procedural sedation may be needed. Transfer or arrange immediate higher-level evaluation for:

• Sepsis, hemodynamic instability, altered mental status, rapidly progressive infection, or inability to tolerate oral intake.
• Suspected necrotizing infection: pain out of proportion, rapidly advancing erythema or edema, bullae, skin necrosis, crepitus, anesthesia, systemic toxicity, or severe pain extending beyond visible skin findings.
• Concern for deep infection, pyomyositis, septic arthritis, osteomyelitis, septic bursitis requiring aspiration/operative management, flexor tenosynovitis, or deep-space hand infection.
• Periorbital or orbital symptoms, facial abscess near the eye or central face with concern for complex anatomy, dental/deep neck infection, airway symptoms, or floor-of-mouth swelling.
• Perirectal, perianal, genital, scrotal, vulvar, or suspected Bartholin abscess when clinician expertise, equipment, and follow-up are insufficient; any concern for Fournier gangrene requires emergency transfer.
• Large, deep, multiloculated, recurrent, postoperative, or anatomically high-risk abscesses; lesions adjacent to major vessels, nerves, tendons, prosthetic material, or joints.
• Pulsatile lesion, bruit, unexplained expanding mass, or concern for pseudoaneurysm; do not incise.
• Severe immunocompromise, febrile neutropenia, poorly controlled diabetes with systemic illness, or substantial inability to return for reassessment.
• Infants, uncooperative young children, or patients whose pain/anxiety cannot be safely managed with local anesthesia and the urgent care’s available resources.

Diagnostic approach and point-of-care ultrasound

History and examination may identify an obvious superficial collection. When fluctuance is absent, anatomy is uncertain, lesion depth is unclear, or cellulitis versus abscess will change management, point-of-care ultrasound (POCUS) is valuable. Typical abscess findings include a discrete hypoechoic or heterogeneous fluid collection, posterior acoustic enhancement, internal debris, and dynamic swirling of contents with compression. Cellulitis more often produces subcutaneous edema with “cobblestoning” and no organized fluid cavity.

POCUS should also assess collection size, depth, loculations, proximity to vessels or tendons, and whether a lesion is too deep for safe ambulatory drainage. A systematic review and meta-analysis found high diagnostic accuracy for POCUS in suspected skin and soft-tissue abscesses; it also changed management correctly in a meaningful minority of cases. [5] Ultrasound informs but does not replace clinical judgment, and it should not delay transfer when a dangerous infection is suspected.

Routine blood testing is generally unnecessary for a well-appearing patient with a simple superficial abscess. Obtain a wound culture when there is severe infection, recurrent infection, treatment failure, significant immune compromise, unusual exposure, substantial surrounding cellulitis, or concern that results will alter therapy. IDSA recommends culture of pus from abscesses and carbuncles, while recognizing that treatment without culture is reasonable in typical uncomplicated cases. [1]

Management principles

Determine whether the lesion is drainable, whether the patient is stable for outpatient care, and whether antibiotics are indicated in addition to source control. I&D is recommended for abscesses, large furuncles, carbuncles, and inflamed epidermoid cysts with a drainable component. [1]

Antibiotic decisions should be individualized. Traditional guidance emphasizes systemic signs, impaired host defenses, multiple lesions, extremes of age, failure of drainage alone, and extensive surrounding infection. More recent randomized trials found modestly higher cure rates after I&D when trimethoprim-sulfamethoxazole (TMP-SMX) or clindamycin was used compared with placebo in settings with prevalent MRSA. [3,4] This benefit must be balanced against adverse effects, allergy history, resistance patterns, drug interactions, pregnancy considerations, antimicrobial stewardship, and the likelihood of reliable follow-up.

Medication options, precautions, and counseling

Antibiotics are adjuncts, not substitutes for drainage. Select therapy using local susceptibility data and culture results when available. The following are common outpatient options for MRSA-suspected purulent infection after adequate drainage; they are examples, not universal regimens.

• TMP-SMX: For selected adults, a common regimen is one to two double-strength tablets (160 mg TMP/800 mg SMX per tablet) orally every 12 hours for 5 to 7 days; some trial regimens used 320 mg/1,600 mg every 12 hours for 7 days. [3] Pediatric treatment requires weight-based dosing expressed as the TMP component, maximum-dose limits, and independent verification. Avoid in infants younger than 2 months. Use caution or avoid with sulfonamide allergy, significant renal impairment without adjustment, hyperkalemia, folate deficiency, and pregnancy when safer alternatives are appropriate; avoid near term because of neonatal bilirubin concerns. Review interactions with warfarin, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, potassium-sparing diuretics, and other agents that increase potassium or creatinine.
• Clindamycin: A common adult regimen is 300 to 450 mg orally every 6 to 8 hours for 5 to 7 days. Pediatric dosing is weight-based and requires verification of the formulation, maximum dose, local susceptibility, and inducible resistance testing when culture data are available. Counsel regarding diarrhea and the risk of Clostridioides difficile infection; stop the medication and seek evaluation for severe or persistent diarrhea. Hepatic dysfunction may warrant closer monitoring or adjustment depending on severity and duration.
• Doxycycline: A common adult regimen is 100 mg orally every 12 hours for 5 to 7 days. It has MRSA activity in many communities but unreliable activity against group A streptococci; if clinically important nonpurulent cellulitis is also present, select or add streptococcal coverage according to local guidance. Avoid or use only after careful risk-benefit assessment during pregnancy; tetracycline labeling warns about fetal and dental/bone effects. Pediatric use, particularly in children younger than 8 years, should follow current pediatric guidance and individualized risk-benefit assessment. Counsel patients to take with water, remain upright to reduce esophagitis risk, and use sun protection because of photosensitivity. Separate from iron, calcium, magnesium, and antacids.
• Culture-directed beta-lactam therapy: If culture identifies methicillin-susceptible S. aureus or if management is directed at uncomplicated nonpurulent cellulitis without MRSA risk factors, an appropriate beta-lactam may be used according to current guidelines and allergy history. A beta-lactam alone should not be presumed adequate for a purulent abscess in a community with substantial MRSA prevalence.

For pregnancy, lactation, pediatric patients, frail older adults, renal or hepatic impairment, anticoagulation, complex allergy histories, and polypharmacy, medication selection should be individualized. Verify dosing using current prescribing information and a reliable pediatric or renal dosing resource before prescribing.

Abscess incision and drainage procedure

Indications

Perform I&D for a clinically or sonographically confirmed superficial, accessible, drainable cutaneous abscess when the patient is stable, pain can be managed safely, nearby anatomy is understood, and outpatient follow-up is feasible.

Relative contraindications and reasons to defer

Defer routine urgent care drainage for the emergency-transfer conditions listed above; unclear diagnosis; suspected vascular lesion; deep or large collection; proximity to critical structures; need for procedural sedation beyond facility capability; uncontrolled bleeding risk; or inability to obtain informed consent or provide appropriate aftercare.

Preparation and equipment

• Personal protective equipment, procedure tray, antiseptic solution, sterile gauze, absorbent dressing, tape, specimen container and culture swab when indicated.
• Local anesthetic, syringe, needles, scalpel with an appropriate blade, hemostat or curved clamp, blunt probe, irrigation supplies, and optional packing material.
• POCUS with high-frequency linear probe and sterile barrier when available and indicated.
• Sharps container, wound-care instructions, and capability for reassessment of vital signs and neurovascular status.

Explain expected benefits, alternatives, and risks, including pain, bleeding, incomplete drainage, need for repeat drainage, scarring, recurrence, infection progression, damage to nearby structures, medication adverse effects, and need for emergency transfer. Obtain and document informed consent. Position the patient comfortably with adequate exposure, lighting, assistance, and safe access to the lesion.

Analgesia and anesthesia

Local anesthesia is often less effective in the acidic, inflamed abscess center. Use a field block through uninvolved surrounding skin when possible. Lidocaine 1% is commonly used; calculate the maximum dose from the patient’s weight and the specific product. A traditional maximum for plain lidocaine is 4.5 mg/kg, not to exceed 300 mg; when epinephrine-containing lidocaine is appropriate, the traditional maximum is 7 mg/kg, not to exceed 500 mg. These limits may not apply in every clinical context and should be reduced or reconsidered in frailty, severe hepatic impairment, low body weight, significant cardiac disease, or when other local anesthetics have been administered. Pediatric dosing must be weight-based and independently verified.

Oral analgesics before the procedure may be useful when not contraindicated. Consider the patient’s anticoagulant use, renal function, hepatic disease, pregnancy, substance use history, and drug interactions before selecting analgesics. Do not exceed the urgent care’s sedation capability.

Step-by-step technique

1. Confirm the target with examination and, when indicated, POCUS. Mark the area of surrounding erythema and identify the point of maximal fluctuance or sonographic collection.
2. Prepare the skin with antiseptic and allow adequate drying time. Drape as appropriate.
3. Administer a field block around, rather than directly into, the most inflamed tissue. Allow time for anesthetic effect.
4. Make a linear incision over the point of maximal fluctuance, generally along relaxed skin tension lines when feasible and with attention to anatomy and dependent drainage. The incision must be large enough to permit evacuation and instrument entry; a tiny stab incision may inadequately drain a loculated cavity.
5. Express purulent material. Obtain a culture from fresh pus before irrigation when culture is indicated.
6. Use a hemostat or blunt probe to gently explore the cavity and break loculations. Avoid deep blind dissection, especially near tendons, nerves, vessels, joints, breast tissue, facial structures, or genital/perirectal anatomy.
7. Irrigate if desired to remove debris. Ensure continued drainage and inspect for retained foreign material or keratinous cyst contents.
8. For most simple cutaneous abscesses, place an external absorbent dressing without routine cavity packing. Evidence has not shown clear outcome benefit from routine packing and suggests increased pain. Packing may still be selectively used for a large cavity, ongoing bleeding, or concern for premature skin closure, but practice varies. [1,6]
9. Apply dressing, reassess hemostasis, pain, distal neurovascular status when relevant, and repeat vital signs if initially abnormal or clinically indicated.

Aftercare, disposition, and follow-up

A clinically stable patient with an adequately drained superficial abscess, controlled pain, reliable follow-up, and no red flags may generally be discharged. Provide written instructions to keep the dressing clean and dry initially, change outer dressings when saturated, wash hands before and after wound care, avoid squeezing or probing the wound, and avoid sharing towels, razors, clothing, or athletic equipment. Encourage completion of prescribed antibiotics when used and review medication-specific adverse effects.

Arrange reassessment in 24 to 48 hours for packed wounds, large cavities, substantial surrounding inflammation, high-risk patients, uncertain adequacy of drainage, or patients with limited self-care capacity. Uncomplicated wounds without packing may require follow-up based on clinical judgment, but patients should have a clear path for prompt reassessment. Review final culture and susceptibility results, contact the patient when therapy should change, and document that communication.

Expected improvement is decreased pain and pressure within 24 to 48 hours; drainage may continue briefly. Induration and erythema can take longer to resolve. Lack of improvement may reflect residual loculations, inadequate incision size, incorrect diagnosis, resistant organism, deep infection, poor adherence, foreign body, or an underlying condition such as hidradenitis suppurativa.

Return and emergency precautions

• Fever, shaking chills, fainting, confusion, vomiting, or worsening generalized illness.
• Rapidly expanding redness, severe or escalating pain, red streaking, new bullae, skin discoloration, numbness, or crepitus.
• Persistent or worsening swelling, failure to drain, recurrent collection, uncontrolled bleeding, or inability to move a nearby joint or digit.
• New eye symptoms, facial swelling, breathing or swallowing difficulty, rectal/genital pain or swelling, or severe diarrhea after antibiotics.
• Allergic reaction symptoms including hives, facial swelling, wheeze, or trouble breathing.

Documentation considerations

• History, risk factors, pregnancy status when relevant, allergies, medications, comorbidities, vital signs, and absence or presence of systemic symptoms.
• Exact lesion location; dimensions; surrounding erythema measurements; fluctuance; drainage; neurovascular and range-of-motion findings when applicable.
• POCUS findings, including depth, dimensions, loculations, and nearby structures, if performed.
• Consent discussion, anesthetic agent/concentration/volume, technique, incision size, amount and character of drainage, probing/loculation disruption, irrigation, culture collection, packing or non-packing decision, dressing, complications, and patient tolerance.
• Antibiotic rationale, culture follow-up plan, discharge condition, follow-up interval, and specific return/emergency precautions.

Clinical takeaways

• Identify a drainable collection; antibiotics alone are inadequate source control for a clinically meaningful abscess.
• Use POCUS when the diagnosis, depth, anatomy, or procedural target is uncertain.
• Make an incision adequate for evacuation and carefully disrupt loculations; incomplete drainage is a common cause of failure.
• Reserve routine urgent care I&D for superficial, accessible lesions in stable patients with reliable follow-up.
• Use adjunctive antibiotics selectively, incorporating systemic findings, host factors, local MRSA resistance, culture data, medication safety, and patient values.
• Routine packing of simple cutaneous abscesses is usually unnecessary and may increase pain.

References

1. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJC, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-e52. doi:10.1093/cid/ciu296.
2. Centers for Disease Control and Prevention. Clinical overview of methicillin-resistant Staphylococcus aureus (MRSA) in healthcare settings [Internet]. Atlanta (GA): CDC; 2025 Jun 27 [cited 2026 Aug 15].
3. Talan DA, Mower WR, Krishnadasan A, Abrahamian FM, Lovecchio F, Karras DJ, et al. Trimethoprim-sulfamethoxazole versus placebo for uncomplicated skin abscess. N Engl J Med. 2016;374(9):823-832. doi:10.1056/NEJMoa1507476.
4. Daum RS, Miller LG, Immergluck L, Fritz S, Creech CB, Young D, et al. A placebo-controlled trial of antibiotics for smaller skin abscesses. N Engl J Med. 2017;376(26):2545-2555. doi:10.1056/NEJMoa1607033.
5. Gottlieb M, Avila J, Chottiner M, Peksa GD. Point-of-care ultrasonography for the diagnosis of skin and soft tissue abscesses: a systematic review and meta-analysis. Ann Emerg Med. 2020;76(1):67-77. doi:10.1016/j.annemergmed.2020.01.004.
6. Mohamedahmed AYY, Zaman S, Stonelake S, Ahmad AN, Datta U, Hajibandeh S, Hajibandeh S. Incision and drainage of cutaneous abscess with or without cavity packing: a systematic review, meta-analysis, and trial sequential analysis of randomised controlled trials. Langenbecks Arch Surg. 2021;406(4):981-991. doi:10.1007/s00423-020-01941-9.

Educational disclaimer: This article is intended for clinician education and does not replace individualized clinical judgment, supervision, consultation, local protocols, or current prescribing information. Medication selection and dosing, procedural suitability, pregnancy considerations, pediatric care, renal/hepatic adjustment, and emergency transfer decisions must be independently verified for each patient.

Why dermatology is different in urgent care

Dermatologic complaints are common, but the visible lesion is only the beginning of the assessment. The same description—“red, swollen skin”—may represent cellulitis, an abscess, contact dermatitis, a bite reaction, venous stasis, gout, thrombosis, or an early necrotizing infection. A diffuse rash may be a self-limited viral eruption, urticaria, a medication reaction, or the first visible sign of systemic illness.

The urgent-care clinician therefore has three jobs:

1. Recognize instability and time-sensitive disease.
2. Describe the eruption accurately enough to build a useful differential.
3. Choose a treatment and disposition that fit the most likely diagnosis without masking a dangerous alternative.

This article offers a reusable framework. It is not an encyclopedia of every rash and should not encourage diagnostic certainty when the morphology, history, or trajectory remains unclear.

Begin with the emergency decision

Before naming the eruption, assess the patient. Obtain and interpret a complete set of vital signs. Look for toxic appearance, altered mental status, hypotension, respiratory distress, hypoxemia, rapidly progressive disease, and pain that seems disproportionate to the visible findings.

Immediate emergency evaluation is generally appropriate when any of the following is present:

• Airway symptoms, wheezing, hypotension, syncope, or rapidly evolving multisystem symptoms concerning for anaphylaxis
• Severe pain out of proportion, rapidly spreading edema or erythema, bullae, skin anesthesia, crepitus, ecchymosis, necrosis, or systemic toxicity concerning for necrotizing soft-tissue infection
• Widespread skin pain, blistering, epidermal detachment, or mucosal erosions, especially after a new medication
• Nonblanching petechiae or purpura with fever, toxicity, hypotension, severe headache, neck stiffness, or altered mental status
• Facial or periorbital infection with pain on eye movement, ophthalmoplegia, proptosis, vision change, or severe headache
• Extensive burns, electrical or chemical burns, inhalation injury, circumferential burns, or burns involving critical functional areas
• Rapidly progressive infection in a markedly immunocompromised patient
• Concern for sepsis, compartment syndrome, septic arthritis, or deep-space infection

A normal temperature does not exclude serious infection. Older adults, immunocompromised patients, and patients taking antipyretics or corticosteroids may have muted findings.

Describe first, diagnose second

Precise morphology improves reasoning, documentation, consultation, and follow-up. Avoid using “rash” as the entire examination.

Primary and secondary lesions

• Macule: Flat color change, generally less than 1 cm.
• Patch: Larger flat area of color change.
• Papule: Small, solid, raised lesion.
• Plaque: Raised, broad lesion, often formed by coalescing papules.
• Nodule: Deeper, solid lesion extending into the dermis or subcutaneous tissue.
• Vesicle: Small fluid-filled blister.
• Bulla: Larger fluid-filled blister.
• Pustule: Superficial lesion containing purulent material.
• Wheal: Transient, edematous, raised lesion typical of urticaria.
• Petechiae: Pinpoint nonblanching hemorrhagic lesions.
• Purpura: Larger nonblanching hemorrhagic lesions.
• Scale: Flaking stratum corneum.
• Crust: Dried serum, blood, or purulent exudate.
• Erosion: Superficial epidermal loss.
• Ulcer: Deeper loss extending into the dermis or beyond.
• Excoriation: Linear or punctate erosion caused by scratching.
• Lichenification: Thickened skin with accentuated lines from chronic rubbing.

Document color, border, surface, tenderness, warmth, fluctuance, induration, drainage, blanching, and whether the epidermis is intact. “Nonblanching” means pressure does not temporarily remove the color; it is a finding, not a diagnosis.

Distribution and configuration

Distribution often narrows the differential more than lesion color. Note whether the process is localized or generalized; unilateral or symmetric; flexural or extensor; dermatomal; acral; intertriginous; photo-distributed; or limited to palms, soles, scalp, face, or mucosa.

Configuration may be annular, linear, grouped, targetoid, reticular, confluent, discrete, or following a contact pattern. Ask whether lesions remain fixed or migrate. Individual urticarial wheals generally move or resolve within hours; a painful or purpuric lesion fixed beyond approximately 24 hours should broaden the differential.

Skin findings vary across skin tones. Erythema may appear red, violaceous, gray, or dark brown and can be subtle. Palpation for warmth, edema, induration, and tenderness, comparison with unaffected skin, and inspection in good lighting reduce reliance on redness alone.

Focused history

Time and trajectory

Establish when the first lesion appeared, where it began, and how it changed. Rapid expansion over hours is different from a stable eruption evolving over weeks. Determine whether pain, itching, fever, or systemic symptoms preceded the skin findings.

Symptoms

Clarify whether the dominant symptom is itch, pain, burning, numbness, or drainage. Intense itch supports—but does not prove—an allergic, eczematous, infestational, or urticarial process. Prominent pain raises concern for infection, ischemia, zoster, ulceration, or a severe drug eruption.

Exposures and transmission

Ask about new personal-care products, detergents, adhesives, occupational materials, plants, metals, topical medications, hot tubs, animals, insects, travel, sick contacts, shared bedding, sports, shelters, and congregate living. Ask about water exposure, bites, punctures, injection drug use, tattoos, shaving, and recent procedures when infection is possible.

Medication history

Create a timeline of all prescription drugs, over-the-counter products, supplements, and intermittent medications. Include recent antibiotics, anticonvulsants, allopurinol, nonsteroidal anti-inflammatory drugs, and acetaminophen. A medication taken safely in the past can still be associated with a later severe skin reaction. Record the start date, stop date, dose change, and onset of symptoms.

Host factors

Identify diabetes, peripheral vascular disease, chronic edema, eczema, obesity, renal or hepatic disease, malignancy, HIV, neutropenia, immunosuppressive therapy, pregnancy, and prior resistant organisms. Ask about recurrent abscesses, hidradenitis, household infections, previous dermatologic diagnoses, and response to earlier treatment.

Associated features

Review fever, chills, malaise, sore throat, cough, gastrointestinal symptoms, joint pain, headache, neck stiffness, eye pain, dysuria, genital lesions, facial swelling, dyspnea, and mucosal pain. A “skin complaint” with organ symptoms may be systemic disease.

Focused examination

Expose enough skin to determine the true distribution while preserving privacy. Examine the mouth and other mucosa when a medication reaction, autoimmune blistering process, infection, or systemic eruption is possible. Inspect palms, soles, web spaces, nails, and scalp when relevant.

For localized redness or swelling:

• Measure the involved area in centimeters.
• Mark the border with date and time when useful for follow-up.
• Assess fluctuance, drainage, induration, lymphangitic streaking, and regional nodes.
• Evaluate distal perfusion, sensation, and movement when an extremity is involved.
• Examine joints and bursae separately rather than attributing every painful swelling to cellulitis.
• Look for portals of entry such as fissures, ulcers, tinea pedis, wounds, or foreign bodies.

For facial or periorbital disease, document visual acuity when feasible, pupils, extraocular movements, pain with movement, proptosis, and neurologic findings. For a wound, describe depth, contamination, devitalized tissue, foreign-body risk, neurovascular status, and tetanus history.

Clinical photographs can support comparison and consultation, but only with informed consent and secure storage that follows applicable privacy rules. A photograph does not replace a written examination.

A pattern-based differential

Red, warm, tender skin

Nonpurulent cellulitis is a diffuse bacterial infection without a drainable collection. It is generally unilateral and characterized by warmth, tenderness, edema, and spreading erythema. Bilateral lower-leg redness should prompt serious consideration of mimics such as stasis dermatitis, lymphedema, lipodermatosclerosis, contact dermatitis, or systemic edema.

Abscess is a localized collection of pus. Fluctuance, focal tenderness, pointing, or spontaneous drainage supports the diagnosis, but early or deep abscesses may be indurated without obvious fluctuance. Purulent collections require source-control thinking; simply labeling an abscess “cellulitis” can lead to antibiotic-only treatment when drainage is the primary intervention.

Inflammatory mimics include contact dermatitis, arthropod reactions, gout, pseudogout, superficial thrombophlebitis, deep venous thrombosis, venous stasis, and ruptured cysts. Sharp geometric borders, intense itch, vesiculation, bilateral involvement, chronic pigment change, or lack of tenderness may point away from uncomplicated cellulitis.

Necrotizing soft-tissue infection can initially resemble cellulitis. Severe pain, pain outside the visible erythema, rapid progression, systemic findings disproportionate to the skin examination, tense edema, bullae, ecchymosis, anesthesia, crepitus, or necrosis are major warnings. Imaging or a reassuring laboratory score must not delay surgical evaluation when suspicion is high. CDC guidance identifies early aggressive surgical exploration and debridement, with parenteral antibiotics, as the core treatment.[1]

Pruritic eruption

Contact dermatitis may be irritant or allergic. Distribution is often the clue: linear plant exposure, a watchband pattern, adhesive outline, glove distribution, or rash confined to a newly treated area. Vesicles and weeping may occur acutely; scale and lichenification suggest chronic exposure. Management depends on removal of the trigger, skin-barrier care, and appropriately selected topical anti-inflammatory therapy.

Urticaria consists of transient wheals caused by dermal edema. Ask whether each lesion migrates or disappears within a day. Evaluate for airway, breathing, circulatory, and gastrointestinal involvement. Urticaria alone is not anaphylaxis; conversely, anaphylaxis can occur without visible hives. Intramuscular epinephrine is the first-line treatment for anaphylaxis. Antihistamines are adjuncts and must not delay epinephrine or emergency care.

Scabies should be considered with nocturnal itch, affected close contacts, and lesions in finger webs, wrists, waistline, axillae, genital region, or other characteristic sites. Infants, older adults, and immunocompromised patients may have atypical or extensive involvement. Treatment planning includes appropriate patient therapy, simultaneous management of close contacts when indicated, and laundering or isolation of recently used clothing and bedding.

Tinea often presents as an annular, scaly plaque with an active border, but morphology can be distorted by corticosteroids. A steroid may reduce redness while allowing fungal infection to extend—sometimes termed tinea incognito. Avoid reflexively prescribing combination antifungal-corticosteroid products when the diagnosis is uncertain.

Vesicles, bullae, erosions, or skin pain

Grouped unilateral vesicles in a dermatomal distribution suggest herpes zoster. Evaluate the eye and tip or side of the nose when the ophthalmic division is involved, and urgently escalate ocular symptoms or findings. Disseminated lesions, major immunocompromise, neurologic symptoms, pregnancy-related concerns, or inability to maintain oral therapy may change disposition.

Diffuse skin pain, targetoid or dusky lesions, blistering, epidermal detachment, and mucosal erosions raise concern for Stevens–Johnson syndrome or toxic epidermal necrolysis. Stop suspected nonessential culprit medication when clinically appropriate, do not rechallenge it, and arrange emergency hospital evaluation. The FDA warns that serious reactions including SJS, TEN, and acute generalized exanthematous pustulosis can occur with acetaminophen and can occur even after previous uneventful use.[2]

Drug reaction with eosinophilia and systemic symptoms (DRESS) may begin weeks after a new medication and can involve fever, facial edema, lymphadenopathy, hematologic abnormalities, and liver, kidney, lung, heart, or pancreatic injury. The skin appearance alone does not determine severity. The FDA notes that DRESS commonly begins two to eight weeks after initiating the implicated medicine.[3]

Bullae can also arise from burns, edema, friction, bullous impetigo, autoimmune disease, diabetic bullae, and vascular compromise. Do not intentionally rupture an unexplained tense bulla merely to “see what is underneath.”

Petechiae and purpura

First confirm nonblanching morphology. Then assess the entire patient. Fever or toxicity with rapidly evolving purpura demands emergency evaluation for invasive infection, sepsis, disseminated intravascular coagulation, or purpura fulminans. Other possibilities include thrombocytopenia, medication effects, small-vessel vasculitis, trauma, dependent pressure, and benign localized petechiae.

Distribution, platelet-related bleeding symptoms, abdominal or joint symptoms, renal symptoms, medication history, and hemodynamic status guide testing and disposition. “Petechiae” should not be used as a reassuring final diagnosis.

Ulcers and wounds

Determine whether the wound is traumatic, neuropathic, arterial, venous, pressure-related, inflammatory, infectious, or malignant. Measure length, width, and depth; document the wound base, drainage, odor, surrounding tissue, undermining, exposed structures, perfusion, sensation, and probe-to-bone findings when appropriate.

Poor perfusion, deep infection, exposed tendon or bone, rapidly progressive necrosis, systemic illness, uncontrolled diabetes, or inability to perform wound care should lower the threshold for escalation. Antibiotics do not substitute for debridement, drainage, pressure relief, vascular assessment, glycemic management, or foreign-body removal when those are required.

Testing: use it to answer a question

Many eruptions are clinical diagnoses. Testing is most useful when it can meaningfully change treatment or disposition.

• Point-of-care ultrasound can help distinguish cellulitic edema from a drainable collection and can identify deeper or multiloculated disease. Operator skill and anatomic limitations matter.
• Culture purulent material when disease is severe, recurrent, unusual, treatment has failed, or host factors make the result important. Routine swabbing or aspiration of intact uncomplicated cellulitis is not recommended.[4]
• KOH preparation, when available and performed competently, can support a dermatophyte or yeast diagnosis.
• Viral testing may be appropriate for atypical, disseminated, occupationally consequential, or high-risk vesicular disease.
• Blood tests may be warranted for systemic illness, severe medication reaction, vasculitis, hematologic disease, organ involvement, or complications, but are not routinely necessary for a stable, localized uncomplicated eruption.
• Radiography may identify radiopaque foreign material, bony involvement, or occasionally gas. A negative radiograph does not exclude radiolucent foreign material or necrotizing infection.

Avoid ordering tests to create false reassurance. If the patient requires emergency consultation based on the clinical picture, transfer should not be delayed for nonessential outpatient testing.

Treatment principles and safeguards

Cellulitis

For typical mild nonpurulent cellulitis without systemic signs, therapy should target streptococci. Broader methicillin-resistant Staphylococcus aureus coverage is considered when there is purulence or relevant risk such as penetrating trauma, MRSA elsewhere or colonization, injection drug use, or severe systemic illness. IDSA recommends outpatient treatment only when the patient lacks systemic inflammatory response, altered mental status, or hemodynamic instability; concern for deep infection, severe immunocompromise, adherence barriers, or treatment failure favors hospitalization.[4]

Select the agent using current local guidance. Check allergy phenotype, pregnancy status, renal and hepatic function, interactions, and recent antibiotics. Elevation and treatment of portals of entry—such as interdigital fissuring or tinea pedis—are part of care. Explain that visible redness may not disappear immediately; worsening systemic symptoms, rapid spread, new severe pain, or failure to improve requires reassessment.

Abscess

Incision and drainage is the principal treatment for an accessible uncomplicated cutaneous abscess. Antibiotics are an adjunct based on systemic findings, surrounding infection, lesion burden or location, recurrence, immune status, age extremes, failed initial therapy, and local guidance.[4]

Before performing drainage, consider proximity to major vessels, nerves, joints, the eye, breast, hand, perineum, or cosmetic structures; depth; suspected foreign body; hidradenitis; pilonidal disease; and whether sedation, imaging, or specialty care is required. Document consent, anesthesia, incision, exploration, irrigation if used, packing decision, specimen collection, blood loss, tolerance, and follow-up.

Topical corticosteroids

Match potency and vehicle to the diagnosis, body site, severity, age, and planned duration. Thin skin of the face, eyelids, folds, and genital region is more vulnerable to atrophy and other adverse effects. Occlusion increases absorption. Use extra caution in children and over large surface areas.

Do not use a topical steroid as a diagnostic trial when untreated fungal, bacterial, viral, or parasitic infection remains plausible. Systemic or depot corticosteroids can temporarily suppress visible inflammation and fever, worsen glycemia, and complicate infection recognition. A nonspecific “rash shot” is not a substitute for diagnosis, safety-netting, and follow-up.

Antihistamines and anaphylaxis

For uncomplicated urticaria without anaphylaxis, a second-generation H1 antihistamine is often preferred because it is generally less sedating than first-generation agents. Counsel about medication-specific sedation and impairment. For suspected anaphylaxis, use intramuscular epinephrine promptly, activate emergency response, monitor, and transfer according to protocol. Corticosteroids and antihistamines do not reverse airway obstruction or shock.

Antimicrobial stewardship

Not every crust, wound, or red plaque needs an antibiotic. Conversely, a prescribed antibiotic does not cure a drainable abscess or necrotic tissue. State the working diagnosis, suspected pathogen class, treatment goal, expected response, and reassessment threshold. Avoid adding MRSA coverage to uncomplicated nonpurulent cellulitis without a clinical reason.[4]

Wound and burn care

Clean wounds, remove visible contaminants when safe, assess for retained foreign body and devitalized tissue, and choose a dressing that protects the wound while managing moisture. Review tetanus vaccination and tetanus immune globulin indications based on wound type and immunization history; antibiotics are not used solely to prevent tetanus.[5]

Burn assessment includes mechanism, time, depth, total body surface area, location, circumferential involvement, neurovascular status, inhalation risk, associated trauma, and host factors. Follow current burn-center referral guidance for potentially deep burns, large burns, critical areas, inhalation injury, chemical or electrical injury, poorly controlled pain, significant comorbidity, and pediatric needs beyond local capability.[6]

Disposition and follow-up

Discharge is safest when the patient is clinically stable, the diagnosis and dangerous alternatives have been considered, the treatment can be carried out, and follow-up is realistic.

Give diagnosis-specific instructions plus explicit emergency precautions. Depending on the condition, return immediately for:

• Trouble breathing, throat tightness, faintness, or facial/tongue swelling
• Fever with worsening illness or confusion
• Rapid spread beyond a marked border
• New severe or disproportionate pain
• Dusky skin, blistering, numbness, black discoloration, or crepitus
• Eye pain, vision change, painful eye movement, or new facial swelling
• Mouth, eye, or genital erosions
• Nonblanching rash with systemic symptoms
• Inability to take medication, maintain hydration, or perform wound care

A planned recheck in approximately 24–48 hours is often appropriate for cellulitis, a drained abscess, an uncertain eruption, high-risk host factors, or disease near a critical structure. Earlier review is warranted if the trajectory changes. When dermatology access is limited, do not allow a routine referral to replace emergency escalation for a time-sensitive condition.

Documentation that supports safe care

A strong note makes the clinician’s reasoning visible. Include:

• Onset, progression, symptoms, exposures, medication timeline, prior treatment, and host risks
• Relevant vital signs and general appearance
• Morphology, color, size, distribution, configuration, blanching, warmth, tenderness, induration, fluctuance, drainage, and mucosal involvement
• Relevant ocular, neurologic, vascular, joint, and systemic findings
• Important dangerous alternatives considered and the findings for or against them
• Tests performed, their limitations, and how results changed management
• Procedure details and consent when applicable
• Medication decision, allergy assessment, and relevant dosing considerations
• Disposition rationale, follow-up interval, and specific return precautions
• Consultation or transfer details and informed refusal if applicable

Example medical-decision-making language

Patient is clinically stable and nontoxic with a localized unilateral area of warmth, tenderness, and poorly demarcated erythema. No fluctuance, drainage, bullae, crepitus, anesthesia, pain out of proportion, rapid progression, hypotension, altered mental status, or joint-centered pain. Findings currently favor uncomplicated nonpurulent cellulitis; abscess, necrotizing infection, septic joint, and inflammatory mimics were considered. Outpatient therapy is reasonable given stable vital signs, oral tolerance, reliable follow-up, and absence of severe immune compromise. Border marked. Recheck arranged within 24–48 hours, with immediate emergency precautions for rapid spread, severe pain, systemic illness, blistering, discoloration, numbness, or clinical deterioration.

Adapt this language to the actual encounter. Never import normal findings that were not assessed.

Informed refusal

If a patient declines emergency transfer, a recommended procedure, medication, or further evaluation, assess decision-making capacity and explain the suspected condition, material risks of refusal, alternatives, and warning symptoms. Offer the safest feasible alternative without representing it as equivalent. Document the patient’s stated reason, questions, understanding, decision, witnesses when relevant, and follow-up plan. Provide emergency precautions in writing.

Coding considerations

Code the diagnosis supported at the end of the encounter, not the most dramatic item in the differential. Examples that may apply include:

• R21 — Rash and other nonspecific skin eruption
• L03.90 — Cellulitis, unspecified
• L02.91 — Cutaneous abscess, unspecified
• L50.9 — Urticaria, unspecified
• L25.9 — Unspecified contact dermatitis, unspecified cause
• B35.9 — Dermatophytosis, unspecified
• B02.9 — Zoster without complications

More specific site, laterality, cause, complication, encounter phase, and burn depth or body-surface codes may be required. Verify the current ICD-10-CM code set and payer rules.

Common procedure families include simple or complicated incision and drainage of a cutaneous abscess and removal of a subcutaneous foreign body. Code selection depends on what was actually performed and documented; evaluation-and-management services, supplies, ultrasound, repair, or burn care have separate rules. Do not select a code from a short educational list without checking the current descriptor, bundling edits, documentation, and payer policy.

Clinical pearls

• Describe the lesion before naming it.
• Bilateral lower-leg erythema is often a cellulitis mimic.
• Purulence calls for source-control thinking.
• Pain out of proportion is a warning, not a diagnosis; act on the whole trajectory.
• Do not delay epinephrine in anaphylaxis while waiting for hives.
• Mucosal erosions plus skin pain or blistering require urgent escalation.
• A new medication timeline may be more important than the rash photograph.
• Steroids can distort infection and tinea.
• Marking and measuring a lesion makes follow-up more objective.
• Skin tone changes how erythema appears; palpation and comparison matter.
• A negative test does not overrule a dangerous clinical pattern.
• When certainty is limited, state it and build a safer follow-up plan.

Conclusion

Urgent-care dermatology is less about memorizing hundreds of named eruptions than consistently answering a sequence of practical questions: Is the patient unstable? Is this skin-limited or systemic? What is the morphology and distribution? Is there purulence, mucosal disease, vascular compromise, severe pain, or rapid progression? Does the proposed treatment address the actual process, and could it conceal a dangerous alternative?

A morphology-first examination, disciplined search for red flags, thoughtful antimicrobial and corticosteroid use, and explicit reassessment plan make dermatologic care safer. When the findings suggest anaphylaxis, necrotizing infection, severe cutaneous drug reaction, invasive infection, ocular involvement, or another threat to life or function, the correct urgent-care intervention is timely stabilization and escalation—not a more elaborate outpatient label.

References

1. Centers for Disease Control and Prevention. Clinical guidance for type II necrotizing fasciitis [Internet]. Atlanta: CDC; 2025 Aug 5 [cited 2026 Aug 14]. Available from: https://www.cdc.gov/group-a-strep/hcp/clinical-guidance/necrotizing-fasciitis.html
2. US Food and Drug Administration. Questions and answers: FDA warns of rare but serious skin reactions with the pain reliever/fever reducer acetaminophen [Internet]. Silver Spring (MD): FDA [cited 2026 Aug 14]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/questions-and-answers-fda-warns-rare-serious-skin-reactions-pain-relieverfever-reducer-acetaminophen
3. US Food and Drug Administration. FDA warns of rare but serious drug reaction to the antiseizure medicines levetiracetam and clobazam [Internet]. Silver Spring (MD): FDA; 2023 Nov 28 [cited 2026 Aug 14]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-rare-serious-drug-reaction-antiseizure-medicines-levetiracetam-keppra-keppra-xr-elepsia-xr
4. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJC, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2). doi:10.1093/cid/ciu296. Available from: https://www.idsociety.org/practice-guideline/skin-and-soft-tissue-infections/
5. Centers for Disease Control and Prevention. Clinical guidance for wound management to prevent tetanus [Internet]. Atlanta: CDC; 2025 Jun 10 [cited 2026 Aug 14]. Available from: https://www.cdc.gov/tetanus/hcp/clinical-guidance/index.html
6. American Burn Association. Guidelines for burn patient referral [Internet]. Chicago: American Burn Association [cited 2026 Aug 14]. Available from: https://ameriburn.org/resources/burnreferral/